- Antisense Therapeutics (ANP) has entered a trading halt as it prepares for a big week of news
- The biotech specialist entered the halt before market open as it prepared to release an update on its orphan drug designation (ODD) application
- ANP submitted the application for its Duchenne muscular dystrophy (DMD) treatment, known as ATL1102, to the European Union in August
- Just a few weeks earlier, the company also applied for the same designation with the U.S. Food and Drug Administration (FDA)
- At the same time, ANP is gearing up to announce the details of a capital raise
- However, shareholders will have to wait until the company resumes trade to find out just how much it intends to raise — or even what the funding will be used for
- Before today’s trading halt, ANP shares were trading for 11.5 cents on Monday, November 9
Antisense Therapeutics (ANP) has entered a trading halt as it prepares for a big week of news.
The biotech specialist entered the halt before market open as it prepared to release an update on its orphan drug designation (ODD) application.
ANP submitted the application for its Duchenne muscular dystrophy (DMD) treatment, known as ATL1102, to the European Union in August. Just a few weeks earlier, the company also applied for the same designation with the U.S. Food and Drug Administration (FDA).
Now, it seems Antisense is ready to provide an update on its E.U. application status, with the company set to emerge from the trading halt on Thursday, November 12.
At the same time, ANP is gearing up to announce the details of a capital raise. However, shareholders will have to wait until the company resumes trade to find out just how much it intends to raise — or even what the funding will be used for.
Just yesterday, the healthcare stock announced it was looking to dual-list on the Frankfurt Stock Exchange (FSE).
Overall, a dual-listing will support the business as it expands its overseas investor base and develops the DMD treatment in Europe.
Before today’s trading halt, ANP shares were trading for 11.5 cents on Monday, November 9.